{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:55:21Z","timestamp":1785779721726,"version":"3.56.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:00:00Z","timestamp":1783209600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The PIBD-SETQuality"},{"name":"European Union\u2019s Horizon 2020 Research and Innovation","award":["668023"],"award-info":[{"award-number":["668023"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Infliximab and adalimumab are effective anti-tumor necrosis factor (anti-TNF) therapies for the treatment of pediatric Crohn\u2019s disease (CD). The aim of this study was to compare the effectiveness of infliximab and adalimumab in a real-world cohort of children with CD.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Data from biological-na\u00efve children with luminal CD (age 3-18 years) who commenced anti-TNF and completed at least 1 year of follow-up were collected from the prospective multicenter observational PIBD-SETQuality study. The primary outcome was steroid-free clinical remission (SFCR), defined as clinical remission (weighted pediatric Crohn\u2019s disease activity index [wPCDAI] &lt;12.5) without systemic steroids or luminal surgery at 1 year. The relative risk (RR) of SFCR was calculated using standardization, correcting for the following baseline covariates: age, upfront anti-TNF, C-reactive protein, erythrocyte sedimentation rate, albumin, leukocytes, disease behavior, wPCDAI, perianal disease, and concomitant immunomodulator use. Secondary outcomes included the durability of anti-TNF treatment without luminal surgery.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Between January 1, 2017, and June 14, 2024, 178 patients with anti-TNF were included (infliximab: n\u2009=\u2009121 [68%], adalimumab: n\u2009=\u200957 [32%]). At 12 months, 34\/56 (61%) patients treated with adalimumab and 66\/120 (55%) patients treated with infliximab had reached SFCR. The RR of SFCR at 1 year with adalimumab compared to infliximab was 1.25 (95% confidence interval [CI] 0.94-1.66], P\u2009=\u2009.13. Adalimumab was associated with a significant lower adjusted hazard ratio (aHR) of treatment discontinuation than infliximab in patients with a concomitant immunomodulator (aHR 0.17 [95% CI 0.04-0.75], P\u2009=\u2009.020), adjusted for upfront anti-TNF.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In this prospective cohort of children with CD, adalimumab and infliximab showed comparable clinical effectiveness 1 year after the start of anti-TNF treatment.<\/jats:p>\n <\/jats:sec>\n \n Clinical trial registration<\/jats:title>\n The ClincalTrials.gov ID of this study is NCT03571373.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/crocol\/otag069","type":"journal-article","created":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T19:57:58Z","timestamp":1783281478000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of adalimumab versus infliximab in children with Crohn\u2019s disease: real-world data from the prospective PIBD-SETQuality inception cohort study"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2710-7241","authenticated-orcid":false,"given":"Stephanie A","family":"Vuijk","sequence":"first","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus Medical Centre\u2014Sophia Children\u2019s Hospital , Rotterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renz C W","family":"Klomberg","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus Medical Centre\u2014Sophia Children\u2019s Hospital , Rotterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Katgert","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus Medical Centre\u2014Sophia Children\u2019s Hospital , Rotterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margreet M S","family":"Wessels","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Rijnstate Hospital , Arnhem,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmo","family":"Miele","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Science, Section of Paediatrics, University of Naples \u2018Federico II\u2019 , Naples,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona L","family":"Cameron","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Alderhey Children\u2019s Hospital NHS Trust , Liverpool,","place":["United Kingdom"]},{"name":"Department of Pediatric Gastroenterology, University of Liverpool , Liverpool,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan D","family":"Milovanovich","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Endoscopy, University Children\u2019s Hospital, Tisova Str. No 10 , Belgrade,","place":["Serbia"]},{"name":"Faculty of Medicine, University of Belgrade , Dr Subotica Str. 8, Belgrade,","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafeeq","family":"Muhammed","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Birmingham Children\u2019s Hospital , Birmingham,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Devadason","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Nottingham University Hospitals NHS Trust , Nottingham,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hart","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology, Royal Devon and Exeter Hospital NHS Trust , Exeter,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9397-0900","authenticated-orcid":false,"given":"Dimitris","family":"Rizopoulos","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Erasmus MC , Rotterdam,","place":["the Netherlands"]},{"name":"Department of Epidemiology, Erasmus MC , Rotterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1519-6435","authenticated-orcid":false,"given":"Nicholas M","family":"Croft","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology, Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6035-1182","authenticated-orcid":false,"given":"Lissy de","family":"Ridder","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus Medical Centre\u2014Sophia Children\u2019s Hospital , Rotterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the PIBD-SETQuality Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Focht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Croft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissy de","family":"Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gigi","family":"Veereman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Koletzko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annecarin","family":"Br\u00fcckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Aloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Ruemmele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2026080313263077200_otag069-B1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa161","article-title":"The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update","volume":"15","author":"van Rheenen","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026080313263077200_otag069-B2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910273","article-title":"Tumor necrosis factor\u2019s pathway in Crohn\u2019s disease: potential for intervention","volume":"22","author":"Pagnini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026080313263077200_otag069-B3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/ecco-jcc\/jjac135","article-title":"Paediatric inflammatory bowel disease: a multi-stakeholder perspective to improve development of drugs for children and adolescents","volume":"17","author":"Croft","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026080313263077200_otag069-B4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/MPG.0000000000001850","article-title":"The role of combination therapy in pediatric inflammatory bowel disease: a clinical report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition","volume":"66","author":"Day","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026080313263077200_otag069-B5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1053\/j.gastro.2019.03.022","article-title":"Canadian association of gastroenterology clinical practice guideline for the medical management of pediatric luminal Crohn\u2019s disease","volume":"157","author":"Mack","year":"2019","journal-title":"Gastroenterology"},{"key":"2026080313263077200_otag069-B6","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1007\/s10620-017-4874-6","article-title":"Comparative effectiveness of infliximab versus adalimumab in patients with biologic-na\u00efve Crohn\u2019s disease","volume":"63","author":"Benmassaoud","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2026080313263077200_otag069-B7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.14309\/ajg.0000000000002552","article-title":"Adalimumab vs infliximab in luminal pediatric Crohn\u2019s disease: comparable outcomes in a prospective multicenter cohort study","volume":"119","author":"deBruyn","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026080313263077200_otag069-B8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/ecco-jcc\/jjy156","article-title":"A propensity score-matched comparison of infliximab and adalimumab in tumour necrosis factor-alpha inhibitor-naive and non-naive patients with Crohn\u2019s disease: real-life data from the sicilian network for inflammatory bowel disease","volume":"13","author":"Macaluso","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026080313263077200_otag069-B9","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.cgh.2016.11.024","article-title":"Comparison of infliximab and adalimumab in biologic-naive patients with ulcerative colitis: a nationwide Danish cohort study","volume":"15","author":"Singh","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026080313263077200_otag069-B10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/apt.18110","article-title":"Network meta-analysis: comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn\u2019s disease","volume":"60","author":"Attauabi","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026080313263077200_otag069-B11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","article-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn\u2019s disease: systematic review and network meta-analysis","volume":"72","author":"Barberio","year":"2023","journal-title":"Gut"},{"key":"2026080313263077200_otag069-B12","doi-asserted-by":"publisher","first-page":"e00490","DOI":"10.14309\/ctg.0000000000000490","article-title":"Adalimumab vs infliximab in pediatric patients with Crohn\u2019s disease: a propensity score analysis and predictors of treatment escalation","volume":"13","author":"Bronsky","year":"2022","journal-title":"Clin Transl Gastroenterol"},{"key":"2026080313263077200_otag069-B13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/MPG.0000000000003853","article-title":"Comparison of clinical outcomes in pediatric patients with ileocolonic Crohn\u2019s disease treated with infliximab vs. adalimumab","volume":"77","author":"Fanous","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026080313263077200_otag069-B14","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1093\/ibd\/izad301","article-title":"Durability of adalimumab and infliximab in children with Crohn\u2019s disease: a nationwide comparison from the epi-IIRN cohort","volume":"30","author":"Atia","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026080313263077200_otag069-B15","article-title":"Real-life durability and risk factors for biologic discontinuation in pediatric inflammatory bowel disease: results from the SIGENP IBD registry","volume":"19","author":"Lega","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026080313263077200_otag069-B16","doi-asserted-by":"publisher","first-page":"e035538","DOI":"10.1136\/bmjopen-2019-035538","article-title":"International prospective observational study investigating the disease course and heterogeneity of paediatric-onset inflammatory bowel disease: the protocol of the PIBD-SETQuality inception cohort study","volume":"10","author":"Aardoom","year":"2020","journal-title":"BMJ Open"},{"key":"2026080313263077200_otag069-B17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","article-title":"ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents","volume":"58","author":"Levine","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026080313263077200_otag069-B18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ibd.21649","article-title":"Mathematical weighting of the pediatric Crohn\u2019s disease activity index (PCDAI) and comparison with its other short versions","volume":"18","author":"Turner","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2026080313263077200_otag069-B19","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2026080313263077200_otag069-B20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026080313263077200_otag069-B21"},{"key":"2026080313263077200_otag069-B22","first-page":"666","article-title":"Standardization as a tool for causal inference in medical research","volume":"19","author":"Gharibzadeh","year":"2016","journal-title":"Arch Iran Med"},{"key":"2026080313263077200_otag069-B23","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","article-title":"Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice","volume":"14","author":"Gisbert","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026080313263077200_otag069-B24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","article-title":"Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn\u2019s disease","volume":"8","author":"Ruemmele","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2026080313263077200_otag069-B25","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1007\/s10620-018-4952-4","article-title":"Infliximab versus adalimumab in patients with biologic-na\u00efve Crohn\u2019s disease: is the difference real?","volume":"63","author":"Mogilevski","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2026080313263077200_otag069-B26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2020-322339","article-title":"First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial","volume":"71","year":"2022","journal-title":"Gut Jan"},{"key":"2026080313263077200_otag069-B27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gut.2009.187120","article-title":"Early Crohn disease: a proposed definition for use in disease-modification trials","volume":"59","author":"Peyrin-Biroulet","year":"2010","journal-title":"Gut"},{"key":"2026080313263077200_otag069-B28","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/apt.15685","article-title":"Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn\u2019s disease","volume":"51","author":"Ungaro","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026080313263077200_otag069-B29","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/ecco-jcc\/jjad197","article-title":"Improved clinical outcomes with early anti-tumour necrosis factor alpha therapy in children with newly diagnosed Crohn\u2019s disease: real-world data from the international prospective PIBD-SETQuality inception cohort study","volume":"18","author":"Klomberg","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026080313263077200_otag069-B30","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.3748\/wjg.v29.i18.2784","article-title":"Infliximab vs adalimumab: points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn\u2019s disease","volume":"29","author":"Kim","year":"2023","journal-title":"World J Gastroenterol"},{"key":"2026080313263077200_otag069-B31","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/apt.15643","article-title":"Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease","volume":"51","author":"Gibson","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026080313263077200_otag069-B32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026080313263077200_otag069-B33","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1093\/ibd\/izad307","article-title":"Infliximab monotherapy vs combination therapy for pediatric Crohn\u2019s disease exhibit similar pharmacokinetics","volume":"30","author":"Colman","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026080313263077200_otag069-B34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/ecco-jcc\/jjad121","article-title":"Durability of the first biologic in patients with Crohn\u2019s disease: a nationwide study from the epi-IIRN","volume":"18","author":"Atia","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026080313263077200_otag069-B35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1053\/j.gastro.2023.03.224","article-title":"Comparative effectiveness of anti-TNF in combination with low-dose methotrexate vs anti-TNF monotherapy in pediatric Crohn\u2019s disease: a pragmatic randomized trial","volume":"165","author":"Kappelman","year":"2023","journal-title":"Gastroenterology"},{"key":"2026080313263077200_otag069-B36","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"2026080313263077200_otag069-B37","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"key":"2026080313263077200_otag069-B38","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.dld.2023.12.013","article-title":"Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: post hoc longitudinal analysis of a randomized trial","volume":"56","author":"Schreiber","year":"2024","journal-title":"Dig Liver Dis"},{"key":"2026080313263077200_otag069-B39","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/MPG.0000000000003838","article-title":"Effectiveness of switching to subcutaneous infliximab in pediatric inflammatory bowel disease patients on intravenous maintenance therapy","volume":"77","author":"Gianolio","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026080313263077200_otag069-B40","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/MPG.0000000000002036","article-title":"Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the European Crohn\u2019s and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"67","author":"Turner","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026080313263077200_otag069-B41","doi-asserted-by":"publisher","first-page":"232","DOI":"10.5009\/gnl19433","article-title":"Comparison of long-term outcomes of infliximab versus adalimumab treatment in biologic-na\u00efve patients with ulcerative colitis","volume":"15","author":"Lee","year":"2021","journal-title":"Gut Liver"},{"key":"2026080313263077200_otag069-B42","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/apt.13580","article-title":"Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis","volume":"43","author":"Singh","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2026080313263077200_otag069-B43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.crohns.2014.01.010","article-title":"Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients na\u00efve to anti-TNF therapy: an indirect treatment comparison meta-analysis","volume":"8","author":"Thorlund","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2026080313263077200_otag069-B44","doi-asserted-by":"publisher","first-page":"e61547","DOI":"10.7759\/cureus.61547","article-title":"Efficacy and safety of infliximab versus adalimumab in adult subjects with moderate to severe ulcerative colitis: a systematic review and meta-analysis","volume":"16","author":"Salman","year":"2024","journal-title":"Cureus"},{"key":"2026080313263077200_otag069-B45","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/14712598.2020.1718096","article-title":"Efficacy of tumour necrosis factor-alpha therapy in paediatric Crohn\u2019s disease patients with perianal lesions: a systematic review","volume":"20","author":"Carnovale","year":"2020","journal-title":"Expert Opin Biol Ther"}],"container-title":["Crohn\u2019s & Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag069\/68697917\/otag069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag069\/68697917\/otag069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag069\/68697917\/otag069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:26:39Z","timestamp":1785777999000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otag069\/8725020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag069","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"otag069"}}